[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-aging":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100638508","snrk--vascular-endothelial-aging-100638508",false,"NCT07591337","SNRK & Vascular Endothelial Aging","The Association Between SNRK and Vascular Endothelial Aging","Inclusion Criteria:\n\n1. Aged 18-80 years, with the capacity to make decisions independently or represented by an authorized legal guardian;\n2. Able to provide complete personal information, medical history, and lifestyle history (e.g., smoking and alcohol consumption history);\n3. No history of severe cardiovascular disease, and deemed eligible for inclusion by a physician.\n\nExclusion Criteria:\n\n1. Women who are pregnant or may become pregnant;\n2. Patients with a history of neurological disorders, tumors, severe cardiovascular or pulmonary disease, liver failure, kidney failure, or blood disorders;\n3. Patients who have undergone carotid stenting, carotid endarterectomy, or other similar procedures, or who have unilateral carotid artery occlusion due to any cause;\n4. Patients who have participated in another clinical trial within the past 4 weeks;\n5. Individuals deemed unsuitable for this clinical trial by the investigators.",true,"ALL","18 Years",{"count":20,"type":21},180,"ESTIMATED","OBSERVATIONAL","Cardiovascular diseases pose a serious threat to public health, and their prevalence is on the rise year by year. Vascular aging is an independent risk factor for cardiovascular diseases, and endothelial cell senescence is an early event in vascular aging. Its occurrence can lead to endothelium-dependent vasodilation dysfunction, reduced vascular permeability, and the release of the senescence-associated secretory phenotype (SASP). These vascular pathological changes further damage the vascular media, leading to vascular remodeling and reduced compliance, accelerating the progression of atherosclerosis, and ultimately resulting in cardiovascular diseases such as coronary heart disease and hypertension. Recent research of the investigators has revealed that SNRK, a new member of the AMPK family of cellular energy sensors, plays a key regulatory role in vascular development. Based on this finding, the investigators propose the scientific hypothesis that SNRK responds to both physiological and pathological aging stimuli through differential mechanisms and regulates the process of endothelial cell senescence. In this study, the investigators will explore the correlation between SNRKAS and carotid vascular structure and endothelial function by measuring the levels of the SNRK upstream lncRNA (SNRKAS) in participants' peripheral blood, in conjunction with carotid ultrasound examinations. The findings will provide a solid scientific basis for elucidating new mechanisms underlying the onset and progression of vascular aging and for identifying novel therapeutic targets.",[25],"Vascular Aging",[27,28,29,30,31],"SNRK","carotid atherosclerosis","vascular endothelial cells","cell senescence","vascular aging","RECRUITING","2026-05-12",{"date":35,"type":36},"2026-05-15","ACTUAL",{"date":38,"type":36},"2026-05-01",{"date":40,"type":21},"2029-04-30",{"name":42,"class":43},"Tianjin Medical University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100618167","efficacy-and-safety-of-coenzyme-i-for-injection-on-vascular-aging-100618167","NCT07328100","Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.","A Randomized, Double-blind, Parallel Controlled Clinical Trial to Evaluate the Efficacy of Coenzyme I for Injection in the Treatment of Vascular Aging（Pilot Stydy）","Inclusion Criteria:\n\n1. Ages 40-70 years;\n2. cf-PWV was abnormally elevated and above the upper limit of its age-and blood-pressure matched reference range;\n3. Systolic Blood Pressure \\\u003C 160 mmHg and ≥ 140 mmHg or Diastolic BP \\\u003C 100 mmHg ≥ 90mmHg;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Consumption of foods or medications containing high levels of NAD+, NR, NAM, NMN, or niacin-related components (including Vitamin B3 and natural health products) within 3 months prior to screening；\n2. History of major cardiovascular or cerebrovascular events, including myocardial infarction, angina, stroke, or hospitalization for arterial revascularization；\n3. Systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg；\n4. Diagnosis of malignant tumor；\n5. Known allergy or history of severe adverse reactions to Coenzyme I injection or any of its components；\n6. History of severe allergies or infusion reactions；\n7. Women who are pregnant, breastfeeding, or planning pregnancy；\n8. Severe hepatic or renal dysfunction: ALT or AST \\> 5 times the upper limit of normal; glomerular filtration rate ≤ 30 mL\u002Fmin\u002F1.73 m²；\n9. Concurrent participation in another clinical trial without completion of the follow-up period；\n10. Other conditions deemed by the investigator as unsuitable for inclusion, such as psychiatric or psychological disorders.","40 Years","70 Years",{"count":55,"type":21},60,"INTERVENTIONAL",[58],"NA","Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.",[25,61],"NAD","NOT_YET_RECRUITING","2025-12-28",{"date":65,"type":36},"2026-01-08",{"date":67,"type":21},"2026-01-16",{"date":69,"type":21},"2027-12-31",{"name":71,"class":43},"Shanghai 10th People's Hospital",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":56,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100394279","exclusive-human-milk-in-preterm-neonates-and-early-vascular-aging-risk-factors-neovasc-100394279","NCT04413994","Exclusive Human-milk in Preterm NEOnates and Early VASCular Aging Risk Factors (NEOVASC)","Effects of an Exclusive Human-milk Diet in Preterm NEOnates on Early VASCular Aging Risk Factors (NEOVASC)","NEOVASC","Preterm-born group:\n\nInclusion Criteria:\n\n1. Extremely preterm infants with a birth weight of 500-1250g.\n2. Feeding is NPO or exclusive human milk prior to enrollment.\n3. Parent(s) willing to sign informed consent.-\n\nExclusion Criteria:\n\n1. Infants with a birth weight \\\u003C500g or \\>1250g\n2. Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria\n3. Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.\n4. Presence of major congenital malformation.\n5. Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.\n6. Parent(s) not willing to sign informed consent.\n7. Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).\n\nTerm-born group:\n\nInclusion criteria\n\n1. Term-born children with an adequate birth weight\n2. Parent(s) willing to sign informed consent\n\nExclusion criteria\n\n1. Subjects with acute or chronic illness\n2. Parent(s) not willing to sign informed consent","1 Day","5 Years",{"count":83,"type":21},200,[58],"Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.",[87,25],"Prematurity","2025-08-22",{"date":90,"type":36},"2025-08-29",{"date":92,"type":36},"2020-10-09",{"date":94,"type":21},"2028-06-01",{"name":96,"class":97},"Prolacta Bioscience","INDUSTRY"]